SkinMedica, NYU team up against hyperpigmentation
This article was originally published in The Rose Sheet
Executive Summary
Carlsbad, Calif.-based SkinMedica has exclusive rights to develop and market products based on New York University's technology addressing hyperpigmentation under a deal announced Oct. 26. "Our scientific discovery involves natural products that act by an entirely novel mechanism to modulate skin pigmentation," says Dr. Seth J. Orlow, chair of the Ronald O. Perelman Department of Dermatology at NYU. "The treatment of hyperpigmentation remains a major unmet need," he adds. Mary Fisher, SkinMedica president and CEO, states: "Hyperpigmentation is a very common problem worldwide, with limited treatment options. We look forward to advancing this problem, which has enormous global market potential." SkinMedica sells its products online and to physicians; the firm's offering includes TNS Essential Serum, TNS Recovery Complex and Dermal Repair Cream, priced at $250, $155 and $112, respectively. Competitor DermaQuest markets Skin Lightening Serum and Skin VitaLight, both formulated with melanostatine-5, a peptide it touts as an effective alternative to hydroquinone (1"The Rose Sheet" Dec. 17, 2007)